ERBB2 and neoplasm: Moreover, using a novel mIHC technique, immune infiltrate at baseline and after 2 weeks of anti-HER2 treatment was characterised in its immune cell subpopulations and analysed according to proximity to tumour cells and activity (using co-expression of Ki67 marker to identify proliferating immune cells).